Literature DB >> 7685617

Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique.

B Vojtĕsek1, C J Fisher, D M Barnes, D P Lane.   

Abstract

We studied 51 paired samples of tissue sections and cytosol extracts from patients with breast cancer. A very high affinity monoclonal antibody to human p53 protein, DO-1, and polyclonal serum CM-1 to p53 protein were used for two site ELISA assays and CM-1 was used for immunohistochemistry to detect p53 protein accumulation in breast cancer samples. Eighteen carcinomas were positive for p53 by tissue staining and ELISA assay. Nineteen tumours were negative by ELISA and immunohistochemistry, and 14 cases with low levels of positive staining by immunohistochemistry were negative by the ELISA assay. A statistically significant correlation has been found between the degree of staining and the amount of p53 protein measured by ELISA (Pearson's correlation coefficient r = 0.59, P < 0.00001). Our ELISA assay offers an alternative approach to evaluating the p53 status of breast biopsy material, using cytosol extracts routinely prepared for steroid hormone receptor assays. This assay should also be of general application to other situations where the level of p53 protein needs to be determined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685617      PMCID: PMC1968521          DOI: 10.1038/bjc.1993.234

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; S H Advani; S Benchimol; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Tissue fixation with phenol-formaldehyde for routine histopathology.

Authors:  D Hopwood; W Slidders; G R Yeaman
Journal:  Histochem J       Date:  1989-04

4.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

Authors:  J Bartek; R Iggo; J Gannon; D P Lane
Journal:  Oncogene       Date:  1990-06       Impact factor: 9.867

5.  p53 mutations in colorectal cancer.

Authors:  N R Rodrigues; A Rowan; M E Smith; I B Kerr; W F Bodmer; J V Gannon; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

7.  p53: a frequent target for genetic abnormalities in lung cancer.

Authors:  T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

8.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

9.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  14 in total

1.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

2.  Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors:  H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

3.  p53 accumulation in polynuclear-giant-cells.

Authors:  T Wiethege; B Voss; K M Müller
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  A novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status.

Authors:  M D Thomas; G G McIntosh; J J Anderson; D M McKenna; A H Parr; R Johnstone; T W Lennard; C H Horne; B Angus
Journal:  J Clin Pathol       Date:  1997-02       Impact factor: 3.411

Review 5.  P53, apoptosis, and breast cancer.

Authors:  D M Barnes; R S Camplejohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

6.  p53 protein and its messenger ribonucleic acid in human adrenal tumors.

Authors:  V Adleff; K Rácz; M Tóth; I Varga; A Bezzegh; E Gláz
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

7.  p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions.

Authors:  D Kamel; Y Soini; K Nuorva; A Khalifa; A Mangoud; K Vähäkangas; P Pääkkö
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  p53 protein is absent from the serum of patients with lung cancer.

Authors:  M A Levesque; M D'Costa; E P Diamandis
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

9.  Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation.

Authors:  C J Fisher; C E Gillett; B Vojtĕsek; D M Barnes; R R Millis
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

10.  Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.

Authors:  C M Barton; N R Lemoine
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.